SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
IEEE’s Hard Tech Venture Summit convened innovators at SRI to refine strategies and build new networks.
Drawing on SRI’s unique innovation ecosystem, the startup Medical Devices Corner is seeking to improve cancer surgery by advancing MRI-safe teleoperation.
The Wall Street Journal tech columnist Christopher Mims and SRI Education’s Susan Patrick discuss how AI can strengthen human agency.